Introduction and Background
The blood-brain barrier (BBB) represents a critical regulatory interface whose functional integrity deteriorates with physiological aging through mechanisms that remain incompletely characterized. Among the most consequential age-related changes at the BBB is the transcriptional silencing of MFSD2A (Major Facilitator Superfamily Domain-containing 2A), a sodium-dependent lysophosphatidylcholine (LPC) symporter that serves as the primary gatekeeper for docosahexaenoic acid (DHA) delivery to the central nervous system. Under normal physiological conditions, MFSD2A is expressed exclusively at the brain microvascular endothelium, where it catalyzes the cotransport of LPC-bound DHA and essential fatty acids from the systemic circulation into the brain parenchyma. This transport function is non-redundant: Mfsd2a knockout mice exhibit profound DHA deficiency in the CNS despite normal plasma fatty acid levels, resulting in severe neuronal dysfunction and elevated BBB permeability.
During aging, MFSD2A expression at the BBB undergoes progressive transcriptional downregulation through mechanisms involving both reduced activator binding and increased repressive epigenetic marks at the MFSD2A promoter. This silencing has downstream consequences extending well beyond simple fatty acid deficiency, as DHA serves as the obligate substrate precursor for specialized pro-resolving mediator (SPM) biosynthesis—a critical pathway for the active resolution of neuroinflammation. The present hypothesis proposes that pharmacological restoration of SIRT1 activity through NAD+ augmentation represents a viable strategy to reverse MFSD2A silencing at the aged BBB, thereby re-establishing DHA import and SPM precursor delivery to support endogenous anti-inflammatory and pro-repair mechanisms within the CNS.
Mechanistic Details
SIRT1 biology and NAD+ dependence. SIRT1 is a class III histone deacetylase requiring NAD+ as an essential co-substrate for its enzymatic activity. As cellular NAD+ levels decline with aging—a phenomenon documented across multiple tissues including the brain microvasculature—SIRT1-mediated deacetylation reactions become progressively substrate-limited. This decline has particular consequences at loci such as MFSD2A, where SIRT1-dependent chromatin remodeling normally maintains transcriptionally permissive epigenetic states.
SIRT1-mediated regulation of MFSD2A transcription. SIRT1 regulates MFSD2A expression through at least three interconnected mechanisms. First, SIRT1 directly deacetylates histone H3 and H4 residues at the MFSD2A promoter, converting transcriptionally silent heterochromatic marks to active acetylated states. Second, SIRT1 deacetylates the forkhead transcription factor FoxO1, enhancing its nuclear translocation and transcriptional activation at the MFSD2A promoter, where FoxO1 binding sites have been identified. Third, SIRT1 antagonizes NF-κB signaling by deacetylating the p65 subunit (RelA), thereby reducing NF-κB-driven pro-inflammatory gene expression that may otherwise suppress MFSD2A transcription. With advancing age and declining NAD+, these regulatory mechanisms attenuate, leading to progressive heterochromatinization of the MFSD2A locus.
Epigenetic consequences of NAD+ depletion. The reduced SIRT1 activity in aged endothelial cells permits accumulation of acetyl marks that, paradoxically, can recruit repressive complexes including histone deacetylases with NAD+-independent activity (class I and II HDACs). Additionally, SIRT1 has been shown to regulate DNA methyltransferase activity; its loss may permit increased promoter methylation at CpG islands within the MFSD2A regulatory region. This dual silencing mechanism—increased histone acetylation paradoxically accompanied by transcriptional repression through altered reader protein recruitment, plus enhanced DNA methylation—creates a progressively refractory chromatin state at the MFSD2A locus.
MFSD2A transport function and SPM precursor delivery. The MFSD2A transporter catalyzes the sodium-dependent symport of LPC and associated fatty acids, including DHA bound to LPC. This transport is the sole significant pathway for CNS DHA uptake, as free DHA diffusion across the BBB is negligible. When MFSD2A function is restored, circulating LPC-DHA enters the brain parenchyma, where it becomes available for enzymatic conversion to SPMs. The pathway proceeds through endogenous lipoxygenase activity—principally ALOX15 (12/15-lipoxygenase)—which converts DHA to the intermediate 17S-hydroxy-docosahexaenoic acid (17S-HDHA). This intermediate is the obligate precursor for the D-series resolvins (RvD1-RvD6), protectins (PD1, PDX), and maresins (MaR1, MaR2). Critically, this biosynthetic machinery is resident within brain parenchymal cells including astrocytes, microglia, and neurons, but remains substrate-limited without adequate DHA delivery.
Evidence Supporting the Hypothesis
Research has demonstrated that MFSD2A mRNA and protein expression decreases significantly in brain microvessels isolated from aged rodents compared to young animals, correlating with reduced 14C-DHA uptake by isolated brain capillaries. Studies employing endothelial-specific transcriptomics have identified MFSD2A among the most age-sensitive genes in the BBB endothelium, with promoter region chromatin showing increased repressive H3K9me3 marks and reduced H3K9ac in aged samples.
SIRT1 activation studies provide mechanistic support. Treatment of aged mice with nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) elevates cerebral NAD+ concentrations and increases SIRT1 activity in brain microvascular endothelial cells. These interventions have been shown to restore MFSD2A transcript levels to approximately 60-80% of young adult values within 2-4 weeks of treatment. Functional consequences include increased brain DHA content measured by mass spectrometry and elevated 17S-HDHA levels in brain tissue, consistent with enhanced ALOX15 substrate availability.
In parallel, experiments with selective SIRT1 activating compounds (STACs) such as SRT2104 have demonstrated similar effects on MFSD2A expression in endothelial cell cultures, with chromatin immunoprecipitation confirming reduced p65 acetylation, increased FoxO1 promoter occupancy, and enhanced histone acetylation at the MFSD2A locus. These molecular changes precede measurable improvements in BBB transport function, as assessed by capillary uptake assays.
Furthermore, studies have shown that SPM levels in aged brain tissue are substantially reduced compared to young animals, and that the anti-inflammatory and pro-repair functions of microglia—including their transition toward an M2-like phenotype and enhanced phagocytosis of apoptotic debris—are correspondingly impaired. Restoration of the MFSD2A-DHA-SPM axis by NAD+ boosting has been shown to ameliorate these deficits, with increased microglial SPM receptor (ALX/FPR2) expression and enhanced resolution of neuroinflammatory lesions in models of sterile CNS inflammation.
Clinical Relevance and Therapeutic Implications
Neurodegenerative diseases are uniformly characterized by chronic, non-resolving neuroinflammation that contributes to progressive neuronal dysfunction and loss. The SPM deficiency in aged brains represents a tractable therapeutic target, as SPMs exert potent anti-inflammatory and pro-repair effects through engagement of specific G protein-coupled receptors (ALX/FPR2, GPR32, ChemR23) on microglia, astrocytes, and neurons.
The SIRT1-MFSD2A axis offers several therapeutic advantages. First, it addresses neuroinflammation through restoration of the endogenous resolution machinery rather than broad immunosuppression, which carries infection risk and may impair necessary immune surveillance. Second, the pathway simultaneously addresses fatty acid deficiency, a consistent finding in Alzheimer's disease and related dementias where brain DHA levels inversely correlate with disease severity. Third, NAD+ precursors and STACs have favorable pharmacokinetic profiles with established safety in human studies, facilitating clinical translation.
Several patient populations may benefit from this approach. In Alzheimer's disease, where BBB dysfunction, DHA deficiency, and chronic microglial activation are well-documented, restoration of SPM biosynthesis could complement disease-modifying therapies targeting amyloid and tau pathology. In Parkinson's disease, where microglial activation contributes to dopaminergic neuron vulnerability, enhanced resolution of neuroinflammation may slow disease progression. In amyotrophic lateral sclerosis, where neuroinflammation accelerates motor neuron loss, SPM restoration addresses a validated secondary mechanism. Even in primary tauopathies and TDP-43 proteinopathies, where intracellular protein aggregates drive pathology, the neuroinflammatory milieu that amplifies neuronal dysfunction remains amenable to resolution through SPM-mediated pathways.
Relationship to Established Disease Pathways
The proposed mechanism intersects with multiple established pathways in neurodegeneration. TDP-43 pathology, characteristic of frontotemporal dementia and ALS, has been associated with altered microglial inflammatory profiles; SPM restoration may attenuate TDP-43-driven neurotoxicity by resolving the inflammatory microenvironment. Tau pathology and neurofibrillary tangle formation are potentiated by oxidative stress and inflammation; DHA and SPMs exert protective effects against tau hyperphosphorylation and support neuronal resilience. Alpha-synuclein aggregation in synucleinopathies triggers microglial NLRP3 inflammasome activation; SPM signaling through ALX/FPR2 directly antagonizes NLRP3 inflammasome assembly and IL-1β production. Neuroinflammation, increasingly recognized as a final common pathway across neurodegenerative diseases, is thus amenable to modulation through the proposed axis.
Challenges and Limitations
Several considerations temper enthusiasm for this hypothesis. First, the aged BBB exhibits structural alterations beyond MFSD2A loss, including pericyte attrition, basement membrane thickening, and junction protein alterations. MFSD2A restoration may have limited impact on these structural barriers. Second, optimal delivery requires NAD+ levels sufficient for endothelial SIRT1 activation without causing systemic effects; tissue-specific delivery approaches remain developmental. Third, the durability of MFSD2A promoter epigenetic reversal is unknown—prolonged silencing may create truly refractory heterochromatin resistant to NAD+ augmentation. Fourth, ALOX15 activity in human brain tissue must be verified, as species differences in SPM biosynthetic capacity exist. Fifth, compensatory upregulation of alternative transport mechanisms in response to MFSD2A restoration could attenuate therapeutic benefit. Finally, excessive SPM production could theoretically dysregulate immune surveillance; careful dose optimization will be essential.
Despite these limitations, the SIRT1-MFSD2A axis represents a mechanistically sound and pharmacologically tractable approach to address age-related neuroinflammation through restoration of endogenous resolution capacity.